In partnership with

🌱 Reckoning for Seed-Stage

What if multi-stage funds completely dominate seed-stage investing? This isn't a distant possibility—it's a transformation already underway.

The advantages are stark. Multi-stage funds possess enormous capital reserves, powerful brand recognition, and extensive founder networks. They can write larger checks, offer more comprehensive support, and attract the most promising entrepreneurs. Where seed-only firms might offer $500,000, these funds can easily deploy $2-3 million in inception rounds.

Institutional investors are taking notice. Some limited partners (LPs) believe that 75% or more of seed investment returns will come from proven, repeat founders—exactly the population multi-stage funds are best positioned to attract. If this thesis proves correct, specialized seed firms could find themselves increasingly marginalized.

The historical hesitation about taking seed funding from multi-stage firms has dramatically reduced. Entrepreneurs are now more pragmatic, valuing opportunity over traditional signaling concerns. A seed check from a top-tier multi-stage fund is no longer viewed with suspicion but seen as a significant advantage.

This doesn't suggest an immediate extinction of seed-only firms. But it does imply a dramatic restructuring. These firms will need to develop unique value propositions. Perhaps they'll specialize in specific sectors, offer more hands-on support, or focus on founder demographics traditionally underserved by larger funds.

The competitive dynamics are fascinating. Multi-stage funds require massive outcomes to justify their investment model. They're seeking companies with potential $5-10 billion valuations. This creates a natural filtering mechanism, potentially leaving meaningful opportunities for specialized seed investors.

But make no mistake—this is a fundamental transformation of the venture ecosystem. The boundaries between seed and multi-stage investing are dissolving. Capital, networks, and founder preferences are driving a consolidation that would have seemed impossible a decade ago.

Survival will demand radical adaptability. Seed investors must continuously reassess their strategies, develop unique insights, and create genuine differentiation. The era of comfortable, predictable seed investing is over.

For Investors =================================

Discover a variety of venture opportunities in promising startups, experienced venture funds, and a broad-scope approach to accessing the upside of AI innovation with Ignite’s fund-of-funds. Fill out this quick form to share your preferences, and we'll connect you with ideal opportunities.

👋🏼 📺 2024 Look-Back 👋🏼

💵Bay Area Startups Secured Over $15.2B

December fundings continued to come in through the last day of the month, for a total of $15.2B. That was more – by several billion – than any previous December. Unlike November, the bulk of the funding went to applications and development tools, rather than AI and AI infrastructure. Databricks $8.6B funding was at the top of the list, followed by seventeen other megadeals and smaller fundings to 152 other companies.

Exit possibilities in 2025: There are some signs that 2025 will bring a return of more VC-backed companies (now at an all-time high, per Pitchbook) exiting through M&A and IPOs, and providing liquidity to their investors and their LPs.

2024 M&A activity was stifled by fear of regulatory action (e.g. Adobe's $20B acquisition of Figma), plus companies being unwilling to be acquired for less than their 2021 – 2022 sky-high valuations. And there were many acquired as a last resort when they couldn't raise new capital; investors lost on those. We also saw the advent of the “reverse acqui-hire” when Microsoft hired the Inflection AI founders, key talent and supporting teams, and licensed their technology - but didn't acquire the company itself. Amazon used the same playbook with both Adept AI and Covariant, and Google with Character AI.

As we come into 2025, the tech companies that IPO'd in 2024 have a mixed bag of results in the public markets. Biotech has not fared well, with the exception of Septerna. However, those companies in and associated with AI continue to perform well, and that may well influence the 100+ companies who have filed – confidentially or publicly – for IPO and are waiting for the right time. Chime is the latest to file.

Septerna...................... up 18.61%

Ceribell........................ up 46.24%

Rubrik.......................... up 107.34%

Astera Labs...................up 273.97%

Reddit ..........................up 387.97%

Follow us on LinkedIn to stay on top of Bay Area startup fundings, exits, executive & investor activity.

Early Stage:

• Swave Photonics closed a $28.3M Series A, holographic display company, develops chipsets to deliver reality-first spatial computing powered by AI.

• Rembrand closed a $23M Series A, the leading In-Scene Media and Virtual Product Placement platform, using AI to seamlessly integrate brands into video content.

• Deterrence closed a $10.1M Seed, building ultra-scalable, flexible and precise manufacturing capacity with robotics for critical energetics that enable the high-energy effects needed for all weapon systems.

• Abundant closed a $.5M Pre-Seed, specialized human operators to handle cases your Agents can't, ensuring 100% agent reliability while generating training data to improve your models.

• Encore AI closed a $.5M Pre-Seed, a conversational search engine designed for online shopping, starting with secondhand products..

Growth Stage:

• .xAI closed a $1B Series C (addition to $5B Series C from November), building AI to accelerate human scientific discovery and advance our collective understanding of the universe.

• KoBold Metals closed a $537M Series C, discovering the materials critical for the renewable energy revolution using AI and HI.

Around The Valley

// F&F Kicks off 2025

// CXO INSIGHTS @ JPM WEEK

🧬 AI TRANSFORMATION FOR LIFE SCIENCES 🧬

This event, held during JPM Healthtech Week, brings together top executives, innovators, and disruptors to address the balance between driving AI progress and mitigating associated risks. It’s an opportunity to explore next-generation solutions that empower healthcare and life sciences organizations to achieve breakthroughs.

🧬 WHO SHOULD ATTEND?

This invite-only event is designed for senior executives and decision-makers driving innovation and strategy in healthcare, life sciences, and pharmaceutical organizations.

• CXOs and Senior Leaders: CEOs, CIOs, CTOs, CSOs, CISOs, and other executives shaping digital transformation and innovation strategies.

• Healthcare and Pharma Innovators: Leaders driving advancements in drug discovery, clinical trials, and personalized medicine.

(Note: CXO is a sub-event to NEXUS2025, Day1: Life Sciences)

REGISTER TODAY 

Join us for an extraordinary healthcare innovation and networking event where we bring together leading startups, investors, clinicians, and industry leaders passionate about transforming healthcare. Connect, collaborate, and explore new solutions to pressing challenges in life sciences, medical devices, digital health, and beyond.

This is an opportunity to share insights, showcase cutting-edge solutions, and create meaningful connections that can drive real impact.

Save your spot today, and let’s shape the future together!

REGISTER TODAYJ

What We’re Listening To:

Your Feedback Matters!

Our mission is to provide an insider's view of Silicon Valley's undercurrents – insights often overlooked by mainstream sources. While many newsletters offer broad market overviews, we focus on delivering a unique, in-depth understanding of the local ecosystem. We share behind-the-scenes conversations, introduce key players we meet at events, and offer exclusive insights.

Your feedback is crucial in helping us refine our content and maintain the newsletter's value for you and your fellow readers. We welcome your suggestions on how we can improve our offering. [email protected] 

Logan Lemery
Head of Content // Team Ignite

There’s a reason 400,000 professionals read this daily.

Join The AI Report, trusted by 400,000+ professionals at Google, Microsoft, and OpenAI. Get daily insights, tools, and strategies to master practical AI skills that drive results.

Sign up now for free and work smarter, not harder.